A zeolite pharmaceutical excipient composite hemostatic agent and its manufacturing method and application
By mixing natural zeolite with trehalose and other medicinal excipients, a composite hemostatic agent was prepared, which solved the serious problem of exothermic zeolite dressings, achieved efficient hemostatic effect and was not easy to cause secondary burns, significantly improving the shapeability of zeolites and Water absorbent and low cost.
Patent Information
- Application Number
- CN202310021903.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-07
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-01-07
AI Technical Summary
Existing zeolite dressings exothermic heat during the hemostasis process, resulting in the formation of local high-temperature areas, which may cause secondary burns to the wound, limiting its further development.
The natural zeolite is evenly mixed with the pharmaceutical excipients such as trehalose to form a composite hemostatic agent. By washing with deionized water, natural air drying, drying and high-temperature sterilization, sterile zeolite medicinal excipient composite hemostatic agent is prepared. , used to prepare hemostatic patches or gauze to reduce heat exogenous phenomenon.
It achieves efficient bleeding and is not easy to exothermic, avoids secondary burns to the wound, significantly improves the formability and water absorption of the zeolite, and is low in cost.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of hemostatic dressings, and more specifically to a zeolite pharmaceutical excipient composite hemostatic agent, and application of the zeolite pharmaceutical excipient composite hemostatic agent in hemostasis in medical occasions. Background Art
[0002] Uncontrolled massive bleeding is an important factor causing death from war trauma or other accidents. Hemostatic agents play an important role in controlling blood loss and preventing a series of emergencies caused by bleeding. Therefore, it is necessary to develop hemostatic materials with high efficiency, good biocompatibility, practicality and low cost.
[0003] Traditional hemostatic products in clinical practice include hemostatic gauze, bandages, sponges, biological products, oxidized regenerated cellulose, chitosan, and some inorganic materials (kaolin, zeolite). Among them, zeolite materials have a short onset time and high hemostatic efficiency, which has attracted widespread attention. Zeolite is a type of aluminosilicate mineral. Its hemostatic effect may be caused by the combined action of multiple factors: first, zeolite has a cage-like cavity that can release the encapsulated calcium ions and promote blood coagulation; second, the zeolite surface adsorbs plasma proteins to form a "protein crown"; in addition, zeolite can act as a physical barrier and has a water absorption effect, which directly delays blood outflow. In 2002, a fine granular zeolite powder called QuikClot was introduced, which has excellent hemostatic efficiency and is mainly used in emergency situations such as large-scale aortic bleeding in war. However, this zeolite dressing has severe heat release, forming a local high-temperature area, causing secondary burns to the wound, which limits its further development.
[0004] In the process of exploring hemostatic materials, the study found that natural zeolite not only has a highly efficient coagulation effect, but also has significant advantages over QuikClot, such as less heat release and lower cost. In addition, based on natural zeolite, the compatibility of excipients is explored to further optimize the hemostatic performance, and natural zeolite is combined with pharmaceutical excipients to develop a new type of zeolite pharmaceutical excipient hemostatic agent. Summary of the invention
[0005] The purpose of the present invention is to provide a zeolite pharmaceutical auxiliary material composite hemostatic agent with high efficiency and low heat release.
[0006] The present invention adopts the following technical scheme: a zeolite pharmaceutical excipient composite hemostatic agent, the structure of the composite hemostatic agent comprises two substances, zeolite and pharmaceutical excipient, specifically a solid mixture formed by uniformly mixing the zeolite and the pharmaceutical excipient.
[0007] The zeolite is selected from any one or more of X-type zeolite, Y-type zeolite, A-type zeolite, ZSM-5 zeolite, chabazite, clinoptilolite, faujasite, β-zeolite, mordenite, L-type zeolite, P-type zeolite and portlandite.
[0008] The zeolite is produced in Jiangsu, Henan, Liaoning, Shandong, Zhejiang, Fujian and other places.
[0009] Furthermore, the zeolite composition includes: silicon oxide, aluminum oxide, sodium oxide, calcium oxide, potassium oxide, iron oxide, magnesium oxide, titanium oxide and the like.
[0010] Furthermore, the particle size of the zeolite is 0.3 to 3 mm, and more preferably about 1 mm.
[0011] The pharmaceutical excipient is selected from polymer materials such as trehalose, sodium alginate, sodium hydroxypropyl methylcellulose, sodium methylcellulose, carbomer, etc., and is used to increase the formability of zeolite. The preferred material is trehalose.
[0012] Furthermore, the mass proportion of the medicinal excipients in the zeolite medicinal excipient composite hemostatic agent is 0%-90%, preferably 20%.
[0013] The present invention provides a method for preparing a zeolite pharmaceutical excipient hemostatic agent, comprising the following steps:
[0014] (1) selecting natural zeolite, crushing the zeolite into particles, and filtering and screening to obtain uniform zeolite particles with a particle size of about 1 mm;
[0015] (2) washing the obtained uniform zeolite particles with deionized water for three times, air-drying them naturally, and then drying them at 120° C.;
[0016] (3) sterilizing the washed and dried zeolite at high temperature;
[0017] (4) The sterilized zeolite is uniformly mixed with a pharmaceutical excipient in an appropriate proportion to obtain a sterile zeolite pharmaceutical excipient composite hemostatic agent.
[0018] The present invention also provides an application of the zeolite pharmaceutical excipient composite hemostatic agent, wherein the zeolite pharmaceutical excipient composite hemostatic agent is used to prepare a hemostatic patch and / or a hemostatic gauze.
[0019] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0020] The invention adopts natural zeolite in combination with pharmaceutical excipients to obtain a composite hemostatic agent which not only has a good hemostatic effect but also is not easy to release heat, thus avoiding secondary burns to the wound. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 These are the results of investigating the properties of the zeolite in Example 2. In the figure, (A) natural zeolite particle size measurement - volume distribution (B) natural zeolite particle size measurement - volume distribution (C) scanning electron microscopy results (D) zeolite element content (E) zeolite oxide content.
[0022] Figure 2 The results of the in vitro coagulation ability test of zeolite in Example 3 are as follows: (A) coagulation time (n=3); (B) coagulation temperature change curve (n=3, **p<0.05).
[0023] Figure 3 These are the results of investigating the blood coagulation ability of zeolite in vivo in Example 4.
[0024] Figure 4 The results of the investigation of the water absorption of zeolite in Example 5 are shown in the figure, (A) representative pictures of natural zeolite before and after water absorption (B) saturated water absorption (n=3, **p<0.05, ***p<0.01).
[0025] Figure 5 This is the result of investigating the water absorption of the zeolite-trehalose complex in Example 6.
[0026] Figure 6 The results of the in vitro coagulation ability test of the zeolite-trehalose complex in Example 7 are shown in the figure, (A) in vitro coagulation reaction time (n=3) and (B) temperature change (n=3).
[0027] Figure 7 These are the results of the in vitro coagulation ability test of the zeolite-different pharmaceutical excipients complex of Example 8. DETAILED DESCRIPTION
[0028] The present invention is further described below by way of examples.
[0029] Example 1
[0030] The preparation of the zeolite pharmaceutical excipient composite hemostatic agent of the present invention comprises the following steps:
[0031] (1) selecting natural zeolite, crushing the zeolite into particles, and filtering and screening to obtain uniform zeolite particles with a particle size of about 1 mm;
[0032] (2) washing the obtained uniform zeolite particles with deionized water for three times, air-drying them naturally, and then drying them at 120° C.;
[0033] (3) sterilizing the washed and dried zeolite at high temperature;
[0034] (4) The sterilized zeolite is uniformly mixed with trehalose in an appropriate proportion to obtain a sterile zeolite pharmaceutical excipient composite hemostatic agent.
[0035] Example 2
[0036] The characterization of the properties of zeolites includes the following steps:
[0037] Take an appropriate amount of zeolite and place it in a Microtrac particle size analyzer to measure its particle size.
[0038] Take appropriate amount of zeolite, natural zeolite, and natural zeolite after washing / sterilization and place them on the conductive glue, dehydrate and dry them, and then use vacuum coating method to spray gold on the samples. Finally, place the prepared samples under TM-1000 field scanning electron microscope for observation.
[0039] Take appropriate amounts of Zeochuang zeolite, natural zeolite, and natural zeolite after washing / sterilization to determine the element content and oxide content respectively.
[0040] The volume distribution results and the number distribution results both show that the particle size of natural zeolite is about 1 mm. From the electron microscopy results, the zeolite from Zeichuang, the natural zeolite and the natural zeolite after washing / sterilization show irregular void structures under the electron microscope, but there is no obvious difference between the three. At the same time, from the content analysis, it can be seen that there is no significant difference in the content of elements and oxides between natural zeolite, natural zeolite after washing / sterilization and Zeichuang zeolite.
[0041] Example 3
[0042] The in vitro coagulation effect characterization of natural zeolite comprises the following steps:
[0043] Take 2mL of sodium citrate anticoagulated rabbit blood, add different volumes of 0.2M CaCl2 solution, mix well and place in a constant temperature water bath at 37℃, observe the coagulation situation every 30s, investigate the effect of CaCl2 addition on the coagulation time, determine the amount of CaCl2 added that can control the coagulation time at 7-8min (natural coagulation time), and use this amount of CaCl2 as the natural coagulation condition in subsequent drug coagulation experiments.
[0044] Quickly add 0.1 g of zeolite into 2 mL of sodium citrate anticoagulated rabbit blood with adjusted natural clotting time, stir quickly with a clean pipette tip, and then place in a 37°C constant temperature water bath. Tilt the test tube about 45 degrees every 30 seconds to observe the coagulation and measure the blood temperature. When the blood is gel-like and no longer flows when shaken upside down, it is considered to be completely coagulated, and the reaction time is recorded.
[0045] This experiment used purchased sodium citrate anticoagulated rabbit blood. Adding 30μL 0.2M CaCl2 can adjust the coagulation time to 8min. Compared with the zeolite, the time required for coagulation in the natural zeolite group was significantly reduced. (p<0.01). Neither the zeolite nor the natural zeolite generated a large amount of heat during the coagulation process, and the highest temperature after the coagulation reaction was no higher than 34℃.
[0046] Example 4
[0047] The in vivo coagulation effect characterization of natural zeolite comprises the following steps:
[0048] SD rats were used to construct an animal model of bleeding. The femoral artery of the rat's hind leg was cut with scissors. 10g of zeolite and natural zeolite were used as hemostatic materials respectively (zeolite was the positive control group). The hemostatic materials and gauze were quickly placed on the wound for compression and hemostasis, and photos were taken and the time required for clotting was recorded.
[0049] The results of the coagulation experiment in rats are shown in the attached Figure 3 As shown in the results, natural zeolite has a better coagulation speed than zeolite and is a potential hemostatic material.
[0050] Example 5
[0051] The characterization of the water absorption effect of natural zeolite includes the following steps:
[0052] Weigh 1.0g of natural zeolite, natural zeolite washed / sterilized, and Zeolite, with Zeolite as a positive control. Use a 200μL pipette to pipette 100μL of ultrapure water each time and add it to the mixture until it absorbs water to saturation, then stop adding water. Saturation here means that the mixture is completely soaked and does not drip after inversion. Weigh the mixture and record it to calculate its saturated water absorption.
[0053] From the results, we can see (Appendix Figure 4 ), the water absorption of zeolite is poor, and the saturated water absorption capacity is significantly reduced compared with the positive control zeolite. Therefore, it is considered to add auxiliary materials with strong water absorption to improve the zeolite's capacity to accommodate body fluids.
[0054] Example 6
[0055] The characterization of the water absorption effect of the natural zeolite-trehalose composite hemostatic agent includes the following steps:
[0056] The washed / sterilized natural zeolite was mixed with 90, 50, 20, 10, and 0% trehalose to form a 1.0 g mixture, and 100 μL of ultrapure water was pipetted into the mixture with a 200 μL pipette each time and added to the mixture until it was saturated with water. Adding water was stopped. Saturation here means that the mixture is completely soaked and does not drip after being inverted. The mixture was weighed and recorded, and its saturated water absorption was calculated. The results are shown in Table 1.
[0057] Table 1. Water absorption of natural zeolite-trehalose mixture (n=3)
[0058]
[0059]
[0060] From the water absorption results (attached Figure 5) shows that the addition of trehalose can greatly improve the water absorption of natural zeolite raw materials. At the same time, its formability is also improved to a certain extent. In the future, we will continue to investigate the effects of natural zeolite-trehalose mixture on its in vitro coagulation ability and temperature, and screen out the natural zeolite-trehalose mixture ratio that takes into account both water absorption and in vitro coagulation ability.
[0061] Example 7
[0062] The in vitro coagulation effect characterization of the natural zeolite-trehalose composite hemostatic agent comprises the following steps:
[0063] Take 2mL of sodium citrate anticoagulated rabbit blood, add different volumes of 0.2M CaCl2 solution, mix well and place in a constant temperature water bath at 37℃, observe the coagulation situation every 30s, investigate the effect of CaCl2 addition on the coagulation time, determine the amount of CaCl2 added that can control the coagulation time at 7-8min (natural coagulation time), and use this amount of CaCl2 as the natural coagulation condition in subsequent drug coagulation experiments.
[0064] 0.1 g of natural zeolite-trehalose mixture after washing / sterilization in different proportions was quickly added to 2 mL of sodium citrate anticoagulated rabbit blood with adjusted natural coagulation time, and the mixture was quickly stirred with a clean pipette tip. The mixture was then placed in a 37°C constant temperature water bath. The test tube was tilted about 45 degrees every 30 seconds to observe the coagulation and record the blood temperature. The blood was considered to be completely coagulated when it was gel-like and no longer flowed when shaken upside down, and the reaction time was recorded.
[0065] This experiment used purchased sodium citrate anticoagulated rabbit blood. Adding 30 μL 0.2M CaCl2 can adjust the coagulation time to 8.0 min. The in vitro coagulation time comparison results are shown in the attached figure. Figure 6 As shown, compared with the natural zeolite material alone, the addition of trehalose has no significant effect on the coagulation time. However, when the trehalose ratio exceeds 50%, the trehalose with strong water absorption will quickly absorb blood into a viscous mass, which may have a certain impact on the coagulation ability of the zeolite. Therefore, the preferred ratio is 20%. From the temperature change results, it can be seen that the natural zeolite-pharmaceutical excipient mixture used in the experiment did not generate a large amount of heat during the coagulation process, and the highest temperature after the coagulation reaction was completed was not higher than 37°C. Theoretically, as the trehalose ratio increases, the zeolite ratio decreases, and thus the coagulation ability will also decrease, but the effect of the ratio change on the coagulation time may be affected by the operating error and the time interval (observation every 30 seconds), so there is no significant difference.
[0066] Example 8
[0067] The screening of pharmaceutical excipients for the natural zeolite-pharmaceutical excipient composite hemostatic agent comprises the following steps:
[0068] Take 2mL of sodium citrate anticoagulated rabbit blood, add different volumes of 0.2M CaCl2 solution, mix well and place in a constant temperature water bath at 37℃, observe the coagulation situation every 30s, investigate the effect of CaCl2 addition on the coagulation time, determine the amount of CaCl2 added that can control the coagulation time at 7-8min (natural coagulation time), and use this amount of CaCl2 as the natural coagulation condition in subsequent drug coagulation experiments.
[0069] Quickly add 0.1g of washed / sterilized natural zeolite-different pharmaceutical excipients mixture into 2mL sodium citrate anticoagulated rabbit blood with adjusted natural coagulation time, stir quickly with a clean pipette tip, and then place in a 37℃ constant temperature water bath. Tilt the test tube about 45 degrees every 30 seconds to observe the coagulation and record the blood temperature. When the blood is gel-like and no longer flows when shaken upside down, it is considered to be completely coagulated, and the reaction time is recorded.
[0070] This experiment used purchased sodium citrate anticoagulated rabbit blood. Adding 30 μL 0.2M CaCl2 can adjust the coagulation time to 8.0 min. The in vitro coagulation time comparison results are shown in the attached figure. Figure 7 As shown, compared with the natural zeolite material alone, the addition of 20% trehalose, sodium hydroxypropyl methylcellulose, sodium methylcellulose and carbomer can increase the blood coagulation ability of zeolite to a certain extent. Among them, the addition of 20% trehalose has the most obvious increase in the blood coagulation effect, so trehalose is the preferred pharmaceutical excipient.
Claims
1. A zeolite pharmaceutical excipient composite hemostatic agent, characterized in that: The composite hemostatic agent is a solid mixture formed by uniformly mixing zeolite and pharmaceutical excipients; The mass proportion of medicinal excipients in the composite hemostatic agent is 10%-50%; The pharmaceutical excipient is trehalose.
2. The composite hemostatic agent according to claim 1, characterized in that: The zeolite is selected from any one or more of X-type zeolite, Y-type zeolite, A-type zeolite, ZSM-5 zeolite, chabazite, clinoptilolite, faujasite, β-zeolite, mordenite, L-type zeolite, P-type zeolite and portlandite.
3. The composite hemostatic agent according to claim 1, characterized in that: The zeolite composition includes any one or more of silicon oxide, aluminum oxide, sodium oxide, calcium oxide, potassium oxide, iron oxide, magnesium oxide and titanium oxide.
4. The composite hemostatic agent according to claim 1, characterized in that: The particle size of the zeolite is 0.3-3 mm.
5. A method for producing the zeolite pharmaceutical excipient composite hemostatic agent according to any one of claims 1 to 4, characterized in that: The steps include: (1) Select natural zeolite and crush it into uniform zeolite particles with a particle size of 0.3~3mm; (2) washing the obtained uniform zeolite particles with water, air-drying them naturally, and then drying them at 110-130°C; (3) sterilizing the zeolite; (4) The sterilized zeolite is uniformly mixed with pharmaceutical excipients to obtain a zeolite pharmaceutical excipient composite hemostatic agent.
6. Use of the zeolite pharmaceutical excipient composite hemostatic agent as claimed in any one of claims 1 to 4 or the zeolite pharmaceutical excipient composite hemostatic agent obtained by the manufacturing method of claim 5, characterized in that: The zeolite medicinal auxiliary material composite hemostatic agent is used for preparing a hemostatic patch and / or a hemostatic gauze.
